EHL Bio is an R&D center established to find ways to overcome various diseases and aging. We lead the development of stem cell therapies (stem cell isolation, storage, culture, etc.), which are the core of future regenerative medicine. commercialization of therapies, and development of immune cell therapies. EHL Bio's research centers on the treatment of diseases such as neurological diseases, osteoarthritis, circulatory diseases, metabolic diseases, autoimmune diseases such as neurological diseases, osteoarthritis, circulatory diseases, metabolic diseases, and autoimmune diseases, as well as anti-aging and health improvement, Alopecia cure, Esthetic care, etc. for the purpose of regenerative medicine. We continuously improve the expertise of our research personnel, and innovate stem cell application technologies to contribute to the improvement of human health around the world. to improve the health of humanity around the world. Contact 📞+82-2-532-9855 🎀HP : http://www.ehlbio.co.kr/eng 📸Insta : https://www.instagram.com/ehlbio_official/ 📱Facebook : https://www.facebook.com/EHLBiocellcenter/ 💛Kakao : https://pf.kakao.com/_Kxklxgb ✅Blog : https://blog.naver.com/ehlbio9883

1. IMMUNE CELL

2. VISION
WhatWeDo
ImmuneCell
CancerCell
Anti-cancerimmunotherapy
NKCell
DendriticCell
TCell
StemCell
ImmuneCellBankingProgram
ImmuneCelltreatmentProgram
Direction
................................
................................
................................
................................
................................
................................
................................
................................
................................
................................
................................
................................
03
05
07
08
09
10
13
15
17
18
19
22
02
The time in EHL flows
for your happiness

3. EHL
BIO
03
E
H
L
Esthetic
Health
Longevity

4. EHL
BIO
04
Find the Future in the EHL
EHL is making a strong leap to become a bio company
that the world is paying attention to.
EHL Bio is an R&D Institute established to search for solutions against diverse
diseases and aging to live a healthy life and extend the human life span.
EHL Bio leads the practical use of innovative treatments based on the development
of stem cell and immune cell therapeutics and clinical experiences.
EHL Bio strives to cure diverse diseases including neurological, osteoarthritis,
circulatory, metabolic, and autoimmune diseases, anti-aging, health promotion, hair
loss treatment, and cosmetic dermatology through research and development of
regenerative medicine.

5. EHL
BIO
05

6. EHL
BIO
06
What we do
EHL Protects your life.
사진
Apply to all diseases caused by poor
function of organ or tissue function
(cirrhosis, diabetes, hypertension,
Parkinson’s, rheumatoid arthritis, etc.)
Anti-aging treatment
Advantages in kidney and genitourinary
disease treatment.
Published the world’s first paper to
identify the klotho secretion from UDSCs.
The world’s first phase 1 clinical trial of
autologous urine-derived stem cell
(UDSC) for chronic kidney disease (CKD).
Immune cells (NK, T, DC) remove foreign
substances and wastes and destroy
cancer cells
The world’s first phase 2 clinical trials
of autologous adipose-derived stem
cell intravenous injections for atopic
dermatitis
The world’s first phase 1 clinical trial of
autologous urine-derived stem cell
(UDSC) for chronic kidney disease (CKD)
Autoimmune disease treatment
(rheumatoid arthritis, etc.)
EHL-STEM™ contains various growth
factors, and cytokines such as EGF, FGF,
VEGF, fibronectin, and collagen useful
for skin rejuvenation. (supply to over 50
domestic and international countries)
SupremeX™ provides an optimal
formulation for culturing various types of
stem cells and immune cells
-
-
-
-
-
- -
-
-
-
-
Adipose-derived stem cell Urine-derived stem cell Immune cells Development of
Cell therapeutics
Stem Cell Conditioned
Media / Cell Culture
Media
Regenerative medicine Regenerative medicine Immunotherapy
1 5
3 4
2

7. EHL
BIO
07
The immune system can defeat invading disease-causing germs (or pathogens), such
as bacteria, viruses, parasites as well as cancer cells.
But, an underactive immune system allows for chronic infection and cancers, and an
overactive immune system leads to allergies or autoimmune diseases.
Immune cells
Immune cells protect
your body
Phagocytosis
Innateimmunity
- Immunity at birth
- The first response of the body's immune system to
harmful foreign substances
- Non-specific immune system
Acquiredimmunity
- Immunity formed by learning and memorizing while
responding to harmful foreign substances,
- Specific memory responses.
T Cells
CD8 T Cells
CD4 T Cells
B Cells
NK Cell
γδT Cells
Macrophages
Granulocyte Dendritic Cells
Antigen
presentation
<Killer T cells>
Elimination of abnormal
cell, Cell-mediated
immunity
<Helper T cells>
Th1 – CTL/Macrophage activation
Th2 – B cell activation
Induce antibody production
Humoral Immunity
Elimination of abnormal cell Antibody production
Antigen presentation /
Elimination of abnormal cell
Immune Cells Immune cells
Immune cells are divided into innate immunity (macrophages, NK cells) and acquired
immunity (T cell, B cell), and dendritic cells and gamma delta T cells act as the link
between those two immunities.
Attack cells infected with
viruses, or tumor cells
The most potent antigen-
presenting cells against
cancer cells
Recognize specific antigens
specifically targeting cancer
cells and attack
Antibody production
•Phagocytosis of bacteria
•Remove foreign substances and
wastes
•Antigen presentation/anti-viral
•Anti-cancer
NK cell Macrophage
Dendritic Cell
B lymphocyte
T lymphocyte

9. EHL leads a new paradigm
of cancer treatment
Development of anti-cancer drugs
Immune cell response against cancer
Chemotherapeutic
Targeted therapy
Immunotherapy
1st generation
2nd generation
3rd generation
Cancer cells
Causing substance
Cancer cell apoptosis
Cause
side
effect
Cancer cell
apoptosis
Cure
Cancer
Injection
Injection
Injection
Activation Immune cells
Immune
improvement
Immune suppressive substances
Suppression
Attack
Attack
Mechanism of
action of anti-
cancer agents
Mechanism of cancer resistance
Mechanism of tackling cancer resistance
Cancer cells escape from the anti-cancer activity of immune cells by the binding of PD-L1 to the
PD-1 receptor.
PD-1 or PD-L1 antibodies block the binding of PD-L1 on cancer cells to PD-1 receptors on immune
cells, which allows immune cells to induce the immune response against cancer cells.
Immune
Cell
Immune
Cell
Immune
Cell
PD-1 receptor
PD-L1 ligand
Cancer
cell
Cancer
cell
Cancer
cell
Immune checkpoint inhibitor
Lymph
node
Activation of
lymphocyte
Acquired
immunity
Neutrophil
Macrophage
NK cell
Activated
NK cells
B cell
Production tumor
antigen-specific lgG antibodies
Cytotoxic T cell Helper T cell
Antigen-loaded
Dendritic cell
Dendritic cell
③
④
①
②
Cancer cell
death induction
Cancer cell
Cancer antigen
Antigen-specific
anti-cancer
responses
① Activated macrophages activate NK cells
② When activated macrophages and NK cells destroy cancer cells, cancer antigens are absorbed by
dendritic cells
③ Dendritic cells phagocytosed with cancer antigens are labeled on the cell surface
④ When cancer markers are delivered to T cells and B cells, they are activated by cytotoxic T cells
and produce antibodies
⑤ Cancer cell attacks by cancer antigen-specific immune responses ➡ Acquired immunity
09
EHL
BIO
Anti-cancer immunotherapy
Immune
Cell Cancer
cell

10. NK cells are more highly
related to cancer among
immune cells
Natural killer cells, also known as NK cells or large granular lymphocytes, are a type of
cytotoxic lymphocyte critical to the innate immune system. The main function of the
NK cell is to attack and kill cancer cells and virus infected cells.
Incidence of cancer
NK cell activity according to age
NK cell activity in healthy patients and cancer patients
Relative incidence rates for major cancer sites by sex (case/0.1million) ■ Survival rate(%)
17.2 | 76.3
15.0 | 22.7
14.0 | 78.0
10.4 | 34.1
9.0 | 94.1
4.8 | 100.6
3.0 | 10.3
2.9 | 77.8
2.8 | 30.2
2.8 | 81.6
Stomach Thyroid
Lung Breast
Colorectal Colorectal
Liver Stomach
Prostate Lung
Thyroid Liver
Pancreas Cervix
Bladder Bladder
Bile duct Pancreas
Kidney ovary
Male Female
Survival rate
62.8
Survival rate
78.4
19.4 | 100.2
18.9 | 92.3
10.7 | 73.6
9.5 | 73.7
7.2 | 35.8
4.0 | 32.2
3.5 | 79.9
3.0 | 28.0
2.9 | 11.5
2.4 | 64.1
NK
activity
Age
Healthy male
Healthy female
Cancer incidence rates
0
200
400
600
800
pg/ml
Liver Breast Prostate Pancreas Colorectal Normal 10 20 30 40 50 60 70 80 90 100
10
40
20
50
30
60
70
80
Survival rate: 5-Year relative survival
rate of cancer patients in 2011 to 2015
(Survival of more than 100% of thyroid
cancer does not mean that no one
died of thyroid cancer for five years, but
that survival of thyroid cancer patients
is higher compared to the general
population of the same age and gender).
※ Survival rate
10
EHL
BIO
NK Cell

11. EHL
BIO
NKG2D, an NK cell activation marker, is expressed more than 70%, making it an excellent
NK cell compared to other companies.
Super NK Cell Therapy
EHL Bio
Super NK Cell Activity
When NK cells recognize cancer cells, they spray Perforin
on the cell membrane, melt the cell membrane to
puncture it, inject granzyme into the cell membrane to
disassemble the cytoplasm, or cause apoptosis, or inject
water and salt into the cell to cause necrosis.
•Approx. 10% of NK cells in PBMC are proliferated to
more than 90% through the isolation culture process.
(over 90% purity)
•Identified significant anti-cancer effect of NK cells in
high-dose compare to an anti-cancer drug.
Normal cell NK cell
NK cell
MHCⅠ
molecule
No Killing
Killing
Inhibitory
receptor
Activating
receptor
Activating
ligand
Activating
ligand
Tumor cell
or virus
infected cell
(Target cell)
Inhibitory
receptor
Activating
receptor
Perforin
Granzyme
Trail Trail-R1/2
NK Cell
Cancer
Cell
PBMC Expanded NK cells
1 4
0
500
1000
1500
2000
8 11 15 18 22 25 29
Time after administration(days)
Tumor
volume
(mm3)
G1: Negative control
G2: Keycell-I-M(1.33x10^5 cells/head)
G3: Keycell-I-M(6.67x10^5 cells/head)
G5: Cisplatin(2mg/kg)
G4: Keycell-I-M(3.34x10^6 cells/head)
PBMC Expanded NK cells
Cell Count 9.4x106
9.95x109
Purity 9.61% 90.58%
9.61% 90.58%
70%
이상
Tumor Volume
11
EHL’s
NK cell is different.
NK Cell

12. NK cell therapy is proceed by culturing NK cells isolated from the patient's blood in
vitro and then administering them back to the patient. It improves the quality of life of
patients who have been degraded due to side effects of anti-cancer drugs as well as
a cancer treatment.
NK cell
treatment cases
EHL
BIO
12
Case 1 Breast Cancer Before and After NK cell treatment
Case 3 Liver Cancer Before and After NK cell treatment
Case 2 Lung Cancer Before and After NK cell treatment
Case 4 Brain Tumor Before and After NK cell treatment
■ Breast cancer before using NK cells treatment (left)
■ Breast cancer cells decreased after 5 months (right)
■ Liver cancer before using NK cells treatment (left)
■ Liver cancer cells decreased after treatment (right)
■ Lung cancer before using NK cells treatment (left)
■ Lung cancer cells decreased after 3 months (right)
■ Brain tumor before using NK cells treatment (left)
■ Brain tumor cells decreased after treatment (right)
Various cancers can
be treated with NK cell
therapy.
NK Cell
Before After

13. EHL
BIO
Dendritic Cells are antigen presenting cells of the immune system.
Dendritic Cell Vaccination
The most potent antigen presenting cells that allow the
immune system to recognize cancer cells.
Dendritic Cell Collection
The monocytes, which are the
basis of dendritic cells, are taken
from the patient's blood.
Remember Cancer Antigens
Remember the target of cancer
and use it as a command tower.
Vaccine Administration
Dendritic cell vaccines are
administered to the patient.
Accurately Attack Cancer Tissue
Attacks cancer by making
lymphocytes to recognize cancer
targets.
Dendritic cells are taken from the
monocyte layer of the patient's
blood.
It teaches dendritic cells the target
of cancer (cancer antigen), and
incubates them as the commander
of the immune system.
Dendritic cell vaccines are
administered to the lymph nodes of
the patient.
Dendritic cells, which act
as command tower, make
lymphocytes to recognize cancer
targets, activate cytotoxic T cells or
B cells to attack only cancer cells
accurately.
01
02
03
04
13
Dendritic Cell?
Dendritic Cell

14. Dendritic cells (DC) are major determinants of vaccination due to their role in priming
T cell immune responses against a specificcancer cancer antigen.
DC plays a critical role to recognize and destroy cells.
Dendritic cell treatment cases
EHL
BIO
14
■ Patients with metastases from bladder cancer to liver
■ Metastasized cancer cells decreased after 18 weeks of DC
vaccine treatment
■ Tumors occurred in glial cells of the brain
■ Tumor size reduced after DC vaccine and 6 sessions of
T cells treatment
■ Combined therapy of DC vaccine + GEM / S-1
(Anti- pancreatic cancer agents)
■ Over 99% of cancer antigen decreased in blood of two
individual patients with late-stage pancreatic cancer
■ Patients with metastases from bladder cancer to lymph node
■ 50% reduction in cancer tissue size after DC vaccine treatment
Dendritic Cell Vaccine
Preventing cancer recurrence and
metastasis.
Dendritic Cell
Case 1 Bladder cancer → Liver metastases
Case 3 Glioblastoma Case 4 Pancreatic cancer
Case 2 Bladder cancer → Periaortic lymph node metastases

15. EHL
BIO
T cells are so called because they are predominantly produced in the thymus even
though they originate from bone marrow progenitors. T cells comprise approx. 60%
to 80% of circulating lymphocytes, and T cells circulate the body until they encounter
cancer cells that harbor the target antigen and kill them.
CTL Therapy
Express TCR(T Cell Receptor) that recognize specific antigens specifically targeting cancer cells and cells infected with viruses
Target cell
Peptide
antigen
ClassⅠMHC
molecule
Cytotoxic
T cell
Perforin
Granzymes
Pore
Dying target cell
Released cytotoxic
T cell
CD8 TCR
15
What is the T cell?
T cell

16. T cell treatment cases
EHL
BIO
16
Various cancers can be
treated with T cell therapy.
T cell
■ Patients with metastases from bile ducts to the liver and lungs
■ Tumor size and number are decreased after 20 months
■ Malignant cancerization of melanocytes or nevus cells
(cells of mole)
■ Most of the tumor disappears after about 2 months
■ Malignant melanoma that occurs in multiple sites
■ Multiple tumors are recovered after about 3 years
■ Patients with metastases from breast cancer to liver
■ Cancer tissue disappears from the breast and liver after
14 months
Case 4 Bile duct cancer → Liver and lung metastases
Case 2 Malignant melanoma
Case 3 Malignant melanoma
Case 1 Breast cancer → Liver metastases

17. The unique immunomodulatory properties of Stem cells make them an invaluable cell type for the
repair of tissue/ organ damage caused by chronic inflammation or autoimmune disorders
The regenerative and immunomodulatory potential of stem cells opened up a new
paradigm of treatment for autoimmune diseases.
In severe autoimmune diseases, the use of autologous stem cells can control overactive
immune systems to relieve symptoms and regenerate damaged organs, reducing the
use of immunosuppressants used in the past.
M1 plarization ↓
M2 polariztion ↑
TSG-6 IL-1Ra
IL-10 TGFβ
IDO PGE2
Complement C3
CCL2 IL-1Ra
IDO PGE2
IDO PGE2
HLA-G5
NO HLA-G5
IDO PGE2
Cell-Cell contact
IL-10
TGFβ
SOD3
PGE2 M-CSF
IL-6 IL-10
TGFβ PGE2
Activation ↓
Differentiation ↓
Proliferation ↓
Activation ↓
Differentiation ↓
Proliferation ↓
Activation ↓
Proliferation ↓
Activation ↓
Generation ↑
Activation ↓
Mutation ↓
Activation ↓
Overactive
Underactive
Frequent infections Autoimmune disease
N
e
t
r
o
p
h
i
l
Macrophage Mast cell
D
e
n
d
r
i
t
i
c
c
e
l
l
N
a
t
u
r
e
k
i
l
l
e
r
c
e
l
l
T
r
e
g
u
l
a
t
o
r
y
c
e
l
l
E
f
f
e
c
t
o
r
T
c
e
l
l
B
c
e
l
l
17
EHL
BIO
Immunomodulatory effects
of stem cells
Stem cell

18. The number of immune cells decreases as you get older and moreover the number
of immune cells in cancer patients decreases by one-third than normal. And also In
the lower NK activity group, the cancer incidence rate increased by 1.7 times higher
in men and 2 times higher in women compared to the high NK activity group. And
when, chronic inflammation inhibitor, IL-10, or the immunosuppressive ability of Th2
is decreased, the incidence rate of cancer is getting high. Therefore, it is important to
bank immune cells when you are young and healthy.
Cultivating Process of Super NK Cell
PBMC
isolation
Blood
collection
Activation
proliferation
Mass culture
Harvest
Injection
Canacer
Patient
① Blood collection
② PBMC isolation
③ NK cell activation
① Thawing
② Expansion
③ Final product
Cryopreservation
(6 sessions)
6~7
days
Order
14
days
Day7
Day0
Day0
Day7
Day14
18
EHL
BIO
Now, It is important to
bank your immune cells
Immune Cell Banking Program

19. EHL Combined Immune Cell Therapy
19
Product Program Session Configuration Remarks
P-Dual
①DC+NK
②DC+CTL
8 times
*Non-banking
: Blood tests
(53 types cancer markers)
Not included
: Flights and meals
P-Triple DC+NK+CTL 16 times
S-NK
Super NK 3 times
Super NK 6 times
1 Cycle 2 Cycle
DC
01
02
03
04
05
06
07
08
DC
CTL CTL
CTL CTL
CTL CTL
DC DC
NK NK
NK NK
NK NK
Antigen
presentation
Antigen
presentation
2nd
cancer attack
1st
cancer attack
01
Blood
collection
DC
02
CTL
NK
03
04
EHL
BIO
isolation
Activation
Banking

20. 00
EHL put in consistent effort,
and that effort becomes pay off
34

21. Protect your life
EHL BIO
People who have been unwell
know how precious and
enjoyable their daily life is.
49

22. 22
EHL Cell Center
EHL Building, 136, Apgujeong-ro,
Gangnam-gu, Seoul, Republic of Korea
TEL +82-2-532-9855 | FAX +82-2-514-8027
Hyundai High school
Indeogwon High school
Indeogwon Elementary school
Indeogwon Middle school
Hannam Bridge
Dongho Bridge
Apgujeong station
Indeogwon station
Subway Line 3
Subway Line 4
Sinsa Middle school
3
Headquarters & Research Institute
B 207, Indeogwon IT Valley, 40 Imi-ro,
Uiwang-si, Gyeonggi-do
TEL 02-535-9883~4
TEL +82-2-535-9883~4 | FAX +82-70-4009-6979

23. www.ehlbio.co.kr